Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Professor Brian Kent

Clinical Associate Professor (Clinical Medicine)

 kentbr@tcd.ie

 


Representations

Details Date
Chief Editor-elect, Breathe September 2021
Secretary, Irish Sleep Society 2021
Section editor on Sleep Disorders, Current Opinion in Pulmonary Medicine 2016-2019

Memberships

Membership of Professional Institutions, Associations, Societies

Details Date From Date To
European Respiratory Society
Irish Thoracic Society
British Thoracic Society
American Thoracic Society
Irish Sleep Society
British Sleep Society
American College of Chest Physicians
Stapleton T., Norris L., Clancy K., O Gorman A., Bannan C., Kent B., Conlon P., Nadajaran P., Kerr C., Connolly D., Outcomes of a fatigue management intervention for people with post COVID-19 condition., American Journal of Physical Medicine and Rehabilitation., 103, (5), 2024, p410 - 417, Journal Article, PUBLISHED  TARA - Full Text  DOI
d'Ancona G, Kavanagh JE, Dhariwal J, Hearn AP, Roxas C, Fernandes M, Green L, Thomson L, Nanzer AM, Jackson DJ, Kent BD., Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma., Allergy, 2021, Journal Article, PUBLISHED  DOI
Hearn AP, Kavanagh J, d'Ancona G, Roxas C, Green L, Thomson L, Fernandes M, Kent BD, Dhariwal J, Nanzer AM, Jackson DJ., The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma., The journal of allergy and clinical immunology. In practice, 9, (5), 2021, p2093-2096.e1 , Journal Article, PUBLISHED  DOI
Hearn AP, Hug OD, Somani ZA, Kavanagh J, d'Ancona G, Roxas C, Green L, Thomson L, Fernandes M, Kent BD, Dhariwal J, Nanzer AM, Jackson DJ., Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy., The European respiratory journal, 2021, Journal Article, PUBLISHED  DOI
Dhariwal J, Hearn AP, Kavanagh JE, d'Ancona G, Green L, Fernandes M, Thomson L, Roxas C, Kent BD, Nanzer AM, Jackson DJ., Real-World Effectiveness of Anti-IL-5/5R Therapy in Severe Atopic Eosinophilic Asthma with Fungal Sensitization., The journal of allergy and clinical immunology. In practice, 2021, Journal Article, PUBLISHED  DOI
d'Ancona G, Kent BD., Practical Applications of FeNO Measurement and Inhaler Monitoring Technologies in the Management of Difficult Asthma., The journal of allergy and clinical immunology. In practice, 9, (4), 2021, p1539-1540 , Journal Article, PUBLISHED  DOI
Kavanagh JE, Hearn AP, Dhariwal J, d'Ancona G, Douiri A, Roxas C, Fernandes M, Green L, Thomson L, Nanzer AM, Kent BD, Jackson DJ., Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma., Chest, 159, (2), 2021, p496-506 , Journal Article, PUBLISHED  DOI
Sleep Disorders. in, editor(s)Mayur Bodani, Rafey Faruqui, Nirul Agrawal , Oxford Textbook of Neuropsychiatry. , Oxford University Press. , 2020, [Leschziner GD, Kent BD], Book Chapter, PUBLISHED
Nanzer AM, Chowdhury A, Raheem A, Roxas C, Fernandes M, Thomson L, Green L, Dhariwal J, D'Ancona G, Kent BD, Kelly PA, Jackson DJ., Prevalence and recovery of adrenal insufficiency in steroid-dependent asthma patients receiving biologic therapy., The European respiratory journal, 56, (1), 2020, Journal Article, PUBLISHED  DOI
Kavanagh JE, d'Ancona G, Elstad M, Green L, Fernandes M, Thomson L, Roxas C, Dhariwal J, Nanzer AM, Kent BD, Jackson DJ., Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma., Chest, 158, (2), 2020, p491-500 , Journal Article, PUBLISHED  DOI
  

Page 1 of 8

  

Research Interests

Description Of Research Interests

My research interests include: . How patient behaviours influence disease activity and responses to medical therapy. In particular, how adherence to prescribed treatment can modify outcomes in chronic respiratory and sleep disorders. . The use of biomarkers to guide disease management in people with difficult and severe asthma. . Real world outcomes with targeted biological therapies in severe asthma. . Interactions between sleep disorders & respiratory disease (including COVID-19) in disease outcomes and patient-reported symptom burden. . The clinical management of hitherto under-investigated sleep disorders, including Non-REM sleep parasomnias. . The use of anti-eosinophil biologic agents in the treatment of Eosinophilic Granulomatosis with Polyangiitis.